H.C. Wainwright lowered the firm’s price target on Alnylam Pharmaceuticals to $395 from $405 and keeps a Buy rating on the shares after the FDA issued a complete response letter indicating it would not approve a supplemental new drug application for patisiran for the treatment of cardiomyopathy of ATTR amyloidosis.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on ALNY:
- Alnylam price target lowered to $218 from $237 at Bernstein
- Alnylam price target lowered to $210 from $252 at Evercore ISI
- Alnylam price target lowered to $260 from $265 at TD Cowen
- Alnylam price target lowered to $234 from $250 at BMO Capital
- BridgeBio has positive readthrough from Alnylam’s CRL, says BofA